List of Dexilant Solutab drug patents

Dexilant Solutab is owned by Takeda Pharms Usa.

Dexilant Solutab contains Dexlansoprazole.

Dexilant Solutab has a total of 11 drug patents out of which 1 drug patent has expired.

Expired drug patents of Dexilant Solutab are:

  • US6664276

Dexilant Solutab was authorised for market use on 26 January, 2016.

Dexilant Solutab is available in tablet, orally disintegrating, delayed release;oral dosage forms.

Dexilant Solutab can be used as treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; maintain healing of erosive esophagitis (ee) for up to 6 months.

The generics of Dexilant Solutab are possible to be released after 10 March, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6664276 TAKEDA PHARMS USA Benzimidazole compound crystal
Jan, 2023

(a day ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6664276

(Pediatric)

TAKEDA PHARMS USA Benzimidazole compound crystal
Jul, 2023

(5 months from now)

US8784885 TAKEDA PHARMS USA Controlled release preparation
Oct, 2023

(8 months from now)

US8784885

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation
Apr, 2024

(1 year, 2 months from now)

US9238029 TAKEDA PHARMS USA Multiple PPI dosage form
Jan, 2026

(2 years from now)

US8461187 TAKEDA PHARMS USA Multiple PPI dosage form
Jan, 2026

(2 years from now)

US9011926 TAKEDA PHARMS USA Method for producing granules
Feb, 2026

(3 years from now)

US8461187

(Pediatric)

TAKEDA PHARMS USA Multiple PPI dosage form
Jul, 2026

(3 years from now)

US8871273 TAKEDA PHARMS USA Method for producing granules
Jan, 2028

(4 years from now)

US8871273

(Pediatric)

TAKEDA PHARMS USA Method for producing granules
Jul, 2028

(5 years from now)

US9241910 TAKEDA PHARMS USA Orally-disintegrating solid preparation
Mar, 2029

(6 years from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 26 January, 2016

Treatment: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; Maintain healing of erosive esophagitis (ee) for up to 6 months

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic